132 related articles for article (PubMed ID: 1901348)
1. Treatment of Guillain-Barré syndrome with anti-T cell monoclonal antibodies.
Feasby TE
J Neurol Neurosurg Psychiatry; 1991 Jan; 54(1):51-4. PubMed ID: 1901348
[TBL] [Abstract][Full Text] [Related]
2. In situ antigenic modulation of human graft-infiltrating T cells is induced by OKT3 treatment.
Caillat-Zucman S; Legendre C; Noel LH; Bach JF; Kreis H; Chatenoud L
Transplant Proc; 1990 Aug; 22(4):1782. PubMed ID: 2143860
[No Abstract] [Full Text] [Related]
3. In vivo use of OKT3: main issues for the monitoring of treated patients.
Chatenoud L; Ferran C; Bach JF
Transplant Proc; 1990 Dec; 22(6):2605-8. PubMed ID: 2124743
[No Abstract] [Full Text] [Related]
4. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3.
Kirklin JK; Bourge RC; White-Williams C; Naftel DC; Thomas FT; Thomas JM; Phillips MG
J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282
[TBL] [Abstract][Full Text] [Related]
5. Use of Orthoclone OKT3 monoclonal antibody to reverse acute renal allograft rejection unresponsive to treatment with conventional immunosuppressive regimens.
Monaco A; Goldstein G; Barnes L
Transplant Proc; 1987 Apr; 19(2 Suppl 1):28-31. PubMed ID: 3105137
[No Abstract] [Full Text] [Related]
6. Immunologic monitoring of Orthoclone OKT3-treated patients: the problem of antimonoclonal immune response.
Bach JF; Chatenoud L
Transplant Proc; 1987 Apr; 19(2 Suppl 1):17-20. PubMed ID: 3105135
[No Abstract] [Full Text] [Related]
7. Acute toxicity of anti-CD3 monoclonal antibody in mice: a model for OKT3 first dose reactions.
Alegre M; Depierreux M; Florquin S; Najdovski T; Vandenabeele P; Abramowicz D; Leo O; Deschodt-Lanckman M; Goldman M
Transplant Proc; 1990 Aug; 22(4):1920-1. PubMed ID: 2143864
[No Abstract] [Full Text] [Related]
8. Treatment of acute rejection with anti-T-cell antigen receptor complex alpha beta (T10B9.1A-31) or anti-CD3 (OKT3) monoclonal antibody: results of a prospective randomized double-blind trial.
Waid TH; Lucas BA; Thompson JS; Munch LC; Brown S; Kryscio R; Prebeck R; VanHoy MA; Jezek D
Transplant Proc; 1991 Feb; 23(1 Pt 2):1062-5. PubMed ID: 1899152
[No Abstract] [Full Text] [Related]
9. Clinical development of Orthoclone OKT3.
Cosimi AB
Transplant Proc; 1987 Apr; 19(2 Suppl 1):7-16. PubMed ID: 3105142
[No Abstract] [Full Text] [Related]
10. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.
Goldstein G
Transplant Proc; 1987 Apr; 19(2 Suppl 1):1-6. PubMed ID: 3105134
[No Abstract] [Full Text] [Related]
11. Prospective randomized trial of OKT3- versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation.
Costanzo-Nordin MR; O'Sullivan EJ; Johnson MR; Winters GL; Pifarre R; Radvany R; Zucker MJ; Scanlon PJ; Robinson JA
J Heart Transplant; 1990; 9(3 Pt 2):306-15. PubMed ID: 2113094
[TBL] [Abstract][Full Text] [Related]
12. T lymphocyte activation antigens in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy.
Taylor WA; Hughes RA
J Neuroimmunol; 1989 Sep; 24(1-2):33-9. PubMed ID: 2808686
[TBL] [Abstract][Full Text] [Related]
13. Lymphocyte subpopulations and suppressor cell activity in acute polyradiculoneuritis (Guillain-Barré syndrome).
Hughes RA; Aslan S; Gray IA
Clin Exp Immunol; 1983 Mar; 51(3):448-54. PubMed ID: 6221841
[TBL] [Abstract][Full Text] [Related]
14. Immunological follow-up of renal allograft recipients treated with the BMA 031 (anti-TCR) monoclonal antibody.
Chatenoud L; Ferran C; Legendre C; Kurrle R; Kreis H; Bach JF
Transplant Proc; 1990 Aug; 22(4):1787-8. PubMed ID: 2117809
[No Abstract] [Full Text] [Related]
15. Therapeutic use of the OKT3 anti-T cell monoclonal antibody: mode of action and side effects.
Chatenoud L
Transplant Proc; 1988 Oct; 20(5 Suppl 6):79-83. PubMed ID: 3140452
[No Abstract] [Full Text] [Related]
16. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report.
Tanaka R; Maruyama H; Tomidokoro Y; Yanagiha K; Hirabayashi T; Ishii A; Okune M; Inoue S; Sekine I; Tamaoka A; Fujimoto M
Jpn J Clin Oncol; 2016 Sep; 46(9):875-8. PubMed ID: 27380808
[TBL] [Abstract][Full Text] [Related]
17. A U.S. clinical study of Orthoclone OKT3 in renal transplantation.
Norman DJ; Shield CF; Barry J; Henell K; Funnell MB; Lemon J
Transplant Proc; 1987 Apr; 19(2 Suppl 1):21-7. PubMed ID: 3105136
[No Abstract] [Full Text] [Related]
18. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience.
Costanzo-Nordin MR; O'Sullivan EJ; Hubbell EA; Zucker MJ; Pifarre R; McManus BM; Winters GL; Scanlon PJ; Robinson JA
J Heart Transplant; 1989; 8(4):288-95. PubMed ID: 2504895
[TBL] [Abstract][Full Text] [Related]
19. Immunologic monitoring in OKT3-treated kidney graft recipients.
Zlabinger GJ; Maurer D; Ulrich W; Meron G; Pohanka E; Kovarik J
Transplant Proc; 1990 Aug; 22(4):1777-8. PubMed ID: 2117807
[No Abstract] [Full Text] [Related]
20. Alterations of lymphocyte responsiveness in Guillain-Barré syndrome. Effects of plasma exchange.
Glassman AB; Bennett CE
Transfusion; 1983; 23(5):369-72. PubMed ID: 6604971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
